Mission Statement

The HPTN is dedicated to the discovery and development of new and innovative research strategies to reduce the acquisition and transmission of HIV.

The HIV Prevention Trials Network (HPTN) is a worldwide collaborative clinical trials network that brings together investigators, ethicists, community and other partners to develop and test the safety and efficacy of interventions designed to prevent the acquisition and transmission of HIV. HPTN studies evaluate new HIV prevention interventions and strategies in populations and geographical regions that bear a disproportionate burden of infection.

The HPTN research agenda is focused primarily on the use of integrated strategies: use of antiretroviral drugs (antiretroviral therapy and pre-exposure prophylaxis); interventions for substance abuse, particularly injection drug use; behavioral risk reduction interventions and structural interventions. The HPTN is committed to the highest ethical standards for its clinical trials and recognizes the importance of community engagement in all phases of the research process.

The HPTN was established in 2000, building on the work of the HIV Network for Prevention Trials (HIVNET). HPTN’s Leadership and Operations Center (LOC), is based at FHI 360, Durham, North Carolina. Its Laboratory Center (LC) is at Johns Hopkins University, Baltimore, Maryland and its Statistical and Data Management Center (SDMC) is housed within the Statistical Center for HIV/AIDS Research and Prevention (SCHARP) at the Fred Hutchinson Cancer Research Center in Seattle, Washington. The HPTN Modelling Centre, part of the SDMC, is a collaboration between the Department of Infectious Diseases Epidemiology at Imperial College London and SCHARP.

HPTN receives its funding from three NIH institutes: the National Institute of Allergy and Infectious Diseases, the National Institute of Mental Health and the National Institute on Drug Abuse.

Webinars

The HPTN Leadership and Operations Center (LOC)

The HPTN Statistical and Data Management Center (SDMC)


Conversations with the HPTN

Yaw Agyei, MPH, is a senior international laboratory QA/QC coordinator at the HPTN Laboratory Center at Johns Hopkins University in Baltimore. He has spent the last 19 years working with different African labs to implement many HPTN trials.

Dr. Adaora A. Adimora, chair of the HPTN’s Women at Risk Scientific Committee, is a Sarah Graham Kenan Distinguished Professor of Medicine at the University of North Carolina (UNC) School of Medicine and professor of epidemiology at the UNC Gillings School of Global Public Health in Chapel Hill, N.C. She is a physician epidemiologist with more than 25 years of clinical experience in treating patients living with HIV.

Mduduzi Ngubane, an HPTN 084 Community Working Group member, is a community liaison officer with the South African Medical Research Council, based at the Isipingo Clinical Research Site (CRS) in Durban, South Africa. Ngubane actively advocates for community engagement at the provincial, district, and ward levels in KwaZulu-Natal, including the Provincial AIDS Council (PCA), Operations Sukhuma Sakhe (OSS), and civil society.

Gertrude Nanyonjo, an HPTN 084 Community Working Group member, is the community engagement lead and a senior social sciences coordinator at UVRI-IAVI HIV Vaccine Program in Entebbe, Uganda. She initially worked on an HIV prevention program focusing on youth and adolescents at risk of acquiring HIV in a busy rural center in Southwestern Uganda (Rakai District), where the first HIV case was identified. Nanyonjo has been active in HIV prevention clinical trials and socio-behavioral studies.